Elmind Capital LP Invests $23.49 Million in Celldex Therapeutics, Inc. $CLDX

Elmind Capital LP purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 865,000 shares of the biopharmaceutical company’s stock, valued at approximately $23,493,000. Celldex Therapeutics comprises 6.9% of Elmind Capital LP’s investment portfolio, making the stock its 5th largest position. Elmind Capital LP owned about 1.30% of Celldex Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after purchasing an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Celldex Therapeutics by 12.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 14,979 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Celldex Therapeutics in the second quarter worth about $347,000.

Wall Street Analyst Weigh In

Several research firms have commented on CLDX. UBS Group increased their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Barclays increased their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group raised their price objective on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Stock Up 1.9%

NASDAQ CLDX opened at $32.93 on Thursday. Celldex Therapeutics, Inc. has a 52 week low of $19.52 and a 52 week high of $35.79. The business’s fifty day simple moving average is $31.96 and its 200-day simple moving average is $28.97. The firm has a market cap of $2.58 billion, a PE ratio of -7.73 and a beta of 0.95.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.80 million. Research analysts expect that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.